32.7002.15% ( -0.720 )
Delay Closed: Nov 18, 16:08:04News
Hansoh Pharma climbs 6%
Market Movers·Germany's Drug Price Reform Brings New Opportunities and Challenges to Chinese Drugmakers as Global Peers Reassess Investment
Yicai·- Germany's healthcare cost-cutting reforms have prompted multinational drugmakers like Roche, Eli Lilly, and Pfizer to pause or reduce local investments, creating a strategic shift in the global pharmaceutical industry. - Chinese innovative drug developers are capturing new opportunities amid this shift, evidenced by rising licensing-out deals surpassing USD 139.4 billion this year as global peers turn to China to replenish development pipelines. - However, Chinese drugmakers face potential challenges as European price pressures and stricter local requirements for research, manufacturing, and employment could impact future milestone payments and overseas expansion returns.HSI Opens Down 6 Pts; LENOVO GROUP Dives 2%+; HSBC HOLDINGS Soft
AASTOCKS News·- The Federal Reserve kept interest rates unchanged while US stocks remained steady, and the HSI opened down 6 points at 23,088 points on October 29. - Major tech stocks showed mixed performance, and pharmaceutical stocks led market gains following positive corporate updates and earnings reports. - Other blue chips experienced varied movements as companies released their financial results for the first three quarters.HSI Reverses to Fall 31 Pts at Midday; XIAOMI-W Drops 4%; Z.AI Gains Nearly 10%; LENOVO GROUP Rebounds Over 5%; DUALITYBIO-B Slumps 29%
AASTOCKS News·- The Hong Kong Hang Seng Index closed the morning session down 31 points at 23,180 points amid selling pressure, with major tech stocks broadly under pressure. - Semiconductor and artificial intelligence related stocks rose following overseas gains and favorable sector sentiment driven by Anthropic's initial public offering filing. - DualityBio-B shares slumped 29.36% despite announcing that the Phase III clinical trial for pacmilimab trastuzumab reached its primary study endpoint.
